ProfileGDS5678 / 1418931_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 38% 37% 37% 34% 36% 38% 35% 36% 36% 35% 36% 37% 36% 39% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8996538
GSM967853U87-EV human glioblastoma xenograft - Control 22.8342737
GSM967854U87-EV human glioblastoma xenograft - Control 32.838137
GSM967855U87-EV human glioblastoma xenograft - Control 42.7243634
GSM967856U87-EV human glioblastoma xenograft - Control 52.7809736
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9419338
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8631435
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7979236
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7980836
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7895835
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8241536
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8073337
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8330636
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.890739